Cancer surveillance, obesity, and potential bias

Although Hyuna Sung and colleagues stressed caution in interpreting their ecological study in *The Lancet Public Health* (March, 2019), the naive reader—or the media, as was the case—might conclude that obesity is fuelling the reported disproportionate temporal increases in incidence of obesity-related cancers in young adults. However, there are many arguments against obesity as a causal driver.

First, as the accompanying Comment highlighted, the biological mechanisms for many early-onset cancers are distinct from those of late-onset cancers. In colorectal cancer, the malignancy in which increases among young adults are most striking, the molecular phenotype of early-onset cancer is often an aggressive consensus molecular subtype (CMS), such as CMS-1 or CMS-3, whereas obesity-related cancers generally follow a more canonical CMS-2 pathway. Second, the Article by Sung and colleagues failed to demonstrate sex or racial specificity, which are hallmarks of the obesity–cancer relationship. Finally, the fundamental premise in age-period–cohort modelling attributes cohort effects to modifiable lifestyle or environmental factors, at the absolute rejection of short-term changes in population-level genetic susceptibility. This method ignores the contributory role of epigenetic effects (for example, methylation), which can influence short-term trends.

There is a need for a concerted effort from the research community to bring together wide-ranging disciplines to disentangle the causes of this emerging public health problem. The linked Comment advocates for “further close epidemiological monitoring”. We champion a wider approach, such as that captured by triangulation (the combination of evidence from studies that yield causal estimates with different potential sources of bias, but where these biases are independent), and inclusion of the use of non-conventional approaches, such as instrumental variable analyses.

AGR reports speaker honoraria from Merck Serona and Janssen-Cilag in the last 2 years, outside the scope of this Correspondence. DGE reports other from AstraZeneca, outside the scope of this Correspondence. RMM declares no competing interests. AGR and DGE are supported by the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007).

*Andrew G Renehan, Richard M Martin, D Gareth Evans* andrew.renehan@manchester.ac.uk

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK (AGR); Manchester Cancer Research Centre, National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Manchester M20 4BX, UK (AGR, DGE); Department of Population Health Sciences, Bristol Medical School and MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK (RMM); National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK (RMM); and Genomic Medicine, Division of Evolution and Genomic Sciences, Manchester Academic Health Sciences Centre, Manchester Universities Foundation Trust, Manchester, UK (DGE)

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.